Who is eligible for clinical trial NCT05245500?

Participants must meet the protocol's inclusion criteria for Mesothelioma. The stated age range is 18 Years. Confirm all requirements with the study coordinator.

Does clinical trial NCT05245500 provide travel or cost reimbursement?

Check with the site coordinator at the participating facility for travel and lodging stipend availability, and for which routine-care costs are covered.

🏛️ Verified NIH Record • Updated 2025-12-04

Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion (NCT05245500)

A Phase 1 Multiple Expansion Cohort Trial of MRTX1719 in Patients With Advanced Solid Tumors With Homozygous MTAP Deletion

🟢 Recruiting Phase1 💊 Investigational Drug / Biologic Sponsor: Bristol-Myers Squibb

🩺 Plain-English Summary (8th-Grade Level)

This is a Phase 1, open-label, multicenter, study of the safety, tolerability, PK, PD, and anti-tumor activity of MRTX1719 patients with advanced, unresectable or metastatic solid tumor malignancy with homozygous deletion of the MTAP gene.

Who can join: To join this study, participants generally need to meet the listed inclusion criteria (6 items) and avoid the listed exclusions (8 items).

Location: Mayo Clinic — Phoenix, Arizona

Age range: 18 Years

🧪 Interventions in This Study

MRTX1719 (DRUG)

📋 "Do I Qualify?" — 1-Minute Self Screener

Instant Checklist

Check every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).

Histologically confirmed diagnosis of a solid tumor malignancy with homozygous deletion of the MTAP gene detected in tumor tissue.
Unresectable or metastatic disease.
Presence of a tumor lesion amenable to mandatory biopsy for pharmacodynamic evaluation at baseline and on-study unless Sponsor-confirmed as medically unsafe or infeasible.
Age ≥ 18 years.
Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
Adequate organ function.

Usually NOT eligible if any of the following apply:

Exclusion Criteria
Prior treatment with a PRMT5 or MAT2A inhibitor therapy.
Active brain metastases or carcinomatous meningitis.
History of significant hemoptysis or hemorrhage within 4 weeks of the first dose of study treatment.
Major surgery within 4 weeks of first dose of study treatment.
History of intestinal disease, inflammatory bowel disease, major gastric surgery, or other gastrointestinal conditions (eg, uncontrolled nausea, vomiting, malabsorption syndrome) likely to alter absorption of study treatment or result in inability to swallow oral medications.
Cardiac abnormalities.
Other protocol-defined Inclusion/Exclusion criteria apply.

🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.

📍 All Participating Trial Locations (25 Sites)

Mayo Clinic — Phoenix, Arizona
Sarah Cannon Research Institute (SCRI) - HealthONE Location — Denver, Colorado
Rocky Mountain Cancer Centers, LLP - Oncology — Lone Tree, Colorado
Mayo Clinic — Jacksonville, Florida
Sarah Cannon Research Institute at Florida Cancer Specialists — Orlando, Florida
Local Institution - 124 — Chicago, Illinois
Dana-Farber Cancer Institute — Brookline, Massachusetts
Cancer and Hematology Centers of Western Michigan — Norton Shores, Michigan
Mayo Clinic — Rochester, Minnesota
Rutgers Cancer Institute of New Jersey — New Brunswick, New Jersey
Local Institution - 129 — Mineola, New York
David H Koch, Memorial Sloan Kettering Cancer Center — New York, New York
New york cancer and blood specialists - Oncology — Port Jefferson Station, New York
New york cancer and blood specialists - Oncology — Port Jefferson Station, New York
University of North Carolina - Gastroenterology and Hepatology — Chapel Hill, North Carolina
University of North Carolina — Chapel Hill, North Carolina
Vanderbilt - Ingram Cancer Center — Nashville, Tennessee
Ut Southwestern — Dallas, Texas
Texas Oncology - DFW — Fort Worth, Texas
MDACC — Houston, Texas
South Texas Accelerated Research Therapeutics — San Antonio, Texas
Texas Oncology, P.A. - Oncology — Tyler, Texas
Virginia Cancer Specialists, PC — Fairfax, Virginia
Local Institution - 134 — Seattle, Washington
Local Institution - 108 — Milwaukee, Wisconsin

📞 Contact the Study Coordinator

Phone: (855) 907-3286

Email: Clinical.Trials@bms.com

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Mesothelioma

Olaparib in Patients With HRD Malignant Mesothelioma — Chicago, Illinois
A Study of Sacituzumab Govitecan in People With Mesothelioma — Basking Ridge, New Jersey
Neoadjuvant Durvalumab and Tremelimumab With and Without Chemotherapy for Mesothelioma — Durham, North Carolina
MAGIC AKI: Magnesium for the Prevention of HIOC-Associated AKI — Boston, Massachusetts
Neoadjuvant Immune Checkpoint Blockade in Resectable Malignant Pleural Mesothelioma — Baltimore, Maryland

Explore by condition: All Mesothelioma clinical trials

💡 How to Participate

Check the checklist above to see if you may qualify.
Contact the study coordinator using the phone/email above.
Ask about the visit schedule, what is covered at no cost, and any travel support.
Confirm with your own doctor before making a decision.

🏛️ View Official NIH Record ↗